Mymetics Corp (MYMX)

[bow-tie]

Tollys
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532
https://www.life-sciences-france.com/news/tollys-closes-series-financing-andrew-lloyd-associates-ala-2001-116843.html
https://tollys.fr/tlr3-science/

Tollys’ lead candidate drug is a double-stranded RNA molecule that activates a protein called toll-like receptor 3 (TLR3), which is found on the surface of tumor cells.

When activated, TLR3 kills cancer cells and puts innate immune cells such as dendritic cells on high alert. The immune system is then trained by antigens from dead cancer cells to kill the cancer cells that weren’t destroyed by the drug and prevent regrowth of the tumor via a vaccination-type mechanism.
https://www.diwou.com/2020/05/28/french-startup-secures-e2-3m-to-advance-cancer-rna-immunotherapy/

Poly(I:C) is a synthetic double-stranded RNA, which can be used as the core genetic material of the virosome and induce innate immunity by stimulating Toll-like receptor 3 (TLR3) pathway.
https://https://europepmc.org/article/PMC/PMC7972832#figures-and-tablesinvestorshub.advfn.com/boards/read_msg.aspx?message_id=163268499
Efficacy and safety of an intranasal virosomal respiratory ...
www.researchgate.net › publication › 236053994
Poly(I:C) is a synthetic double-stranded RNA (dsRNA) molecule that induces effective mucosal immune responses by stimulating Toll-like receptor 3 (TLR3) as a molecular mimic of dsRNA, which is a ...

University of Groningen A virosomal respiratory syncytial ...
research.rug.nl › files › 2419204
Mymetics BV Leiden, The Netherlands ... Virosome technology 21 ... (TLRs), such as TLR3 and TLR4,18 underlining the role of this protein in immune evasion.
https://pure.rug.nl/ws/portalfiles/portal/2419204/PhD_thesis_Kamphuis_Pages_corr_1.pdf